Additional file 2: Table S1. of Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
- Pierre Fenaux (751250)
- Aristoteles Giagounidis (89571)
- Dominik Selleslag (4174144)
- Odile Beyne-Rauzy (4174147)
- Moshe Mittelman (504273)
- Petra Muus (4174162)
- Stephen Nimer (4174156)
- Eva HellstrĂśm-Lindberg (4174168)
- Bayard Powell (4004954)
- Agnes Guerci-Bresler (3812443)
- Mikkael Sekeres (3489917)
- H. Deeg (3413975)
- Consuelo del CaĂąizo (4174165)
- Peter Greenberg (4174141)
- Jamile Shammo (4174150)
- Barry Skikne (785629)
- Xujie Yu (4174159)
- Alan List (4174153)
Publication date
June 2017
DOIAbstract
Cumulative rates of AML progression by age group in lenalidomide-treated patients. AML, acute myeloid leukemia; MDS, myelodysplastic syndromes. (DOCX 14Â kb
Add to ORKG